Akorn 1 year target
What is the 1 year target of Akorn?
The 1 year target of Akorn, Inc. is $2 +7,307.41%
What is the definition of 1 year target?
1 year target is a predicted stock price a year from now.
= average of analyst price targets
One year target is an estimate of a stock price for a point in time equal to a year from the current date. The price level most often reflects the collective opinion of different analysts on where the stock will be trading a year from now. For an analyst to identify an individual estimate, they have to project what a company’s business will look like in a year, typically focusing on revenue and other significant factors. They also consider the willingness of investors to pay a certain price. While the average or median recommendation may be predictive and reflect the actual future value, the results are usually not extremely successful.
1 year target of companies in the Health Care sector on OTC compared to Akorn
What does Akorn do?
Akorn, Inc., a specialty pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Further, the company sells its products to wholesale distributors. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois. On May 20, 2020, Akorn, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Companies with 1 year target similar to Akorn
- Carbon Revolution has 1 year target of AUD$2 +1,366.67%
- Pro Farm Inc has 1 year target of $2 +147.50%
- Windward has 1 year target of GBX161 +2.33%
- Clever Leaves has 1 year target of $2 +989,900.00%
- Beach has 1 year target of AUD$2 +73.04%
- LifeSpeak has 1 year target of CAD$2 +362.79%
- Akorn has 1 year target of $2 +7,307.41%
- Shanghai Jin Jiang International Hotels () has 1 year target of HKD$2 -24.53%
- Meridian Mining Uk Societas has 1 year target of CAD$3 +653.12%
- BlueCity has 1 year target of $0 -80.71%
- Helios Towers plc has 1 year target of $2 -98.18%
- Helios Towers PLC has 1 year target of GBX165 +47.69%
- Montage Gold has 1 year target of CAD$2 +12.85%